Mayzent Approved to Treat Multiple Sclerosis

March 28, 2019

03/26/2019 FDA Release

The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

“Multiple sclerosis can have a profound impact on a person’s life,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “We are committed to continuing to work with companies that are developing additional treatment options for patients with multiple sclerosis.”

Mayzent must be dispensed with a patient Medication Guide that describes important information about the drug’s uses and risks.

Read the full release.